Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma

Biomaterials

Volumn 33, Issue 6, 2012, Pages 1808-1820

  Yu, Yang ^a   Wang, Zhao Hui ^a   Zhang, Liang ^a   Yao, Hong Juan ^a   Zhang, Yan ^a   Li, Ruo Jing ^a   Ju, Rui Jun ^a   Wang, Xiao Xing ^a   Zhou, Jia ^a   Li, Nan ^a   Lu, Wan Liang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Breast cancer; Melanoma; Metastases; Mitochondrial targeting topotecan loaded liposomes; Multidrug resistance

Indexed keywords

B16 MELANOMA; BREAST CANCER; CANCER METASTASIS; CASPASES; COLOCALIZATION; CYTOCHROME C; DRUG CONTENT; DRUG RESISTANCE; IN-VITRO; INHIBITORY EFFECT; MCF-7 CELLS; MELANOMA; METASTASES; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MULTIDRUG RESISTANCE; NUDE MICE; TUMOR SPHEROID;

BIOLOGICAL MATERIALS; CELL MEMBRANES; CHEMOTHERAPY; DERMATOLOGY; DISEASES; ENZYME INHIBITION; LIPOSOMES; MAMMALS; ONCOLOGY; PATHOLOGY; PHOSPHOLIPIDS; TUMORS;

MITOCHONDRIA;

BREAST CANCER RESISTANCE PROTEIN; CASPASE 9; CYTOCHROME C; LIPOSOME; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LIPOSOMES; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS; TOPOTECAN;

MUS; MUS MUSCULUS;

EID: 83555179075     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.10.085     Document Type: Article

References (41)

1. Harris A.L., Hochhause D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992, 31(2):205-213.
2. Hawes D., Neville A.M., Cote R.J. Detection of occult metastasis in patients with breast cancer. Semin Surg Oncol 2001, 20(4):312-318.
3. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53(1):615-627.
4. Monceviciute-Eringiene E. Cancer and malignant resistance of cells as phenomena of adaptation to damaging factors. Med Hypothese 1996, 46(5):459-462.
5. Herr I., Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 2001, 98(9):2603-2614.
6. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5(3):219-234.
7. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997, 3(6):614-620.
8. Placzek W.J., Wei J., Kitada S., Zhai D., Reed J.C., Pellecchia M. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis 2010, 1:e40. 10.1038/cddis.2010.18.
9. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281(5381):1309-1312.
10. Modica-Napolitano J.S., Singh K.K. Mitochondrial dysfunction in cancer. Mitochondrion 2004, 4(5-6):755-762.
11. Galeano E., Nieto E., García-Pérez A.I., Delgado M.D., Pinilla M., Sancho P. Effects of the antitumoural dequalinium on NB4 and K562 human leukemia cell lines. Mitochondrial implication in cell death. Leuk Res 2005, 29(10):1201-1211.
12. Weiss M.J., Wong J.R., Ha C.S., Bleday R., Salem R.R., Steele G.D., et al. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc Natl Acad Sci USA 1987, 84(15):5444-5448.
13. Sancho P., Galeano E., Nieto E., Delgado M.D., García-Pérez A.I. Dequalinium induces cell death in human leukemia cells by early mitochondrial alterations which enhance ROS production. Leuk Res 2007, 31(7):969-978.
14. D'Souza G.G., Rammohan R., Cheng S.M., Torchilin V.P., Weissig V. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release 2003, 92(1-2):189-197.
15. Yao H.J., Ju R.J., Wang X.X., Zhang Y., Li R.J., Yu Y., et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 2011, 32(12):3285-3302.
16. Varma M.V., Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005, 25(4-5):445-453.
17. Collnot E.M., Baldes C., Schaefer U.F., Edgar K.J., Wempe M.F., Lehr C.M. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm 2010, 7(3):642-651.
18. Zhang Z., Feng S.S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006, 27(2):262-270.
19. Hatefi A., Amsden B. Camptothecin delivery methods. Pharm Res 2002, 19(10):1389-1399.
20. 2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. J Control Release 2006, 112(2):186-198.
21. Honig A., Rieger L., Sutterlin A., Kapp M., Dietl J., Sutterlin M.W., et al. Brain metastases in breast cancer-an in vitro study to evaluate new systemic chemotherapeutic options. Anticancer Res 2005, 25(3A):1531-1537.
22. Sugimoto Y., Tsukahara S., Ishikawa E., Mitsuhashi J. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci 2005, 96(8):457-465.
23. Yang C.H., Schneider E., Kuo M.L., Volk E.L., Rocchi E., Chen Y.C. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 2000, 60(6):831-837.
24. Zuco V., Supino R., Favini E., Tortoreto M., Cincinelli R., Croce A.C., et al. Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochem Pharmacol 2010, 79(4):535-541.
25. Du J., Lu W.L., Ying X., Liu Y., Du P., Tian W., et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm 2009, 6(3):905-917.
26. Zhang Y.T., Lu W.L., Li T., Liang G.W., Sun J.B., Guo J., et al. A continued study on the stealth liposomal topotecan plus amlodipine: in vitro and in vivo characterization in non-resistant solid tumors. J Health Sci 2008, 54(4):450-463.
27. Ying X., Wen H., Lu W.L., Du J., Guo J., Tian W., et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010, 141(2):183-192.
28. Scaduto R.C., Grotyohann L.W. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 1999, 76(1 Pt 1):469-477.
29. Sharov V.G., Todor A., Khanal S., Imai M., Sabbah H.N. Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol 2007, 42(1):150-158.
30. Petronilli V., Miotto G., Canton M., Brini M., Colonna R., Bernardi P., et al. Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys J 1999, 76(2):725-734.
31. Pozo-Guisado E., Merino J.M., Mulero-Navarro S., Lorenzo-Benayas M.J., Centeno F., Alvarez-Barrientos A., et al. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kB. Int J Cancer 2005, 115(1):74-84.
32. Kostarelos K., Emfietzoglou D., Papakostas A., Yang W.H., Ballangrud A., Sgouros G. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer 2004, 112(4):713-721.
33. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011, 63(3):131-135.
34. Fang J., Nakamura H., Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63(3):136-151.
35. Bogman K., Erne-Brand F., Alsenz J., Drewe J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci 2003, 92(6):1250-1261.
36. Dintaman J.M., Silverman J.A. Inhibition of P-glycoprotein by D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999, 16(10):1550-1556.
37. Sun X.M., MacFarlane M., Zhuang J., Wolf B.B., Green D.R., Cohen G.M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 1999, 274(8):5053-5060.
38. Zoratti M., Szabò I. The mitochondrial permeability transition. Biochim Biophys Acta 1995, 1241(2):139-176.
39. Sheng Y., Liu C., Yuan Y., Tao X., Yang F., Shan X., et al. Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials 2009, 30(12):2340-2348.
40. Awasthi V.D., Garcia D., Goins B.A., Phillips W.T. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm 2003, 253(1-2):121-132.
41. Guo R.R., Liu Y., Lu W.L., Zhao J.H., Wang X.Q., Zhang H., et al. A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma. Biol Pharm Bull 2008, 31(4):696-702.